Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01966757 · ClinicalTrials.gov registry record
Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities
A clinical trial of Batten's Disease and Neuronal Ceroid Lipofuscinosis, sponsored by Nationwide Children's Hospital.
- Completed
- Registry status
- 57
- Enrollment target
- 1
- Study location
NCT01966757: Completed study of Batten's Disease and Neuronal Ceroid Lipofuscinosis, sponsored by Nationwide Children's Hospital.
NCT01966757 is a study of Batten's Disease and Neuronal Ceroid Lipofuscinosis that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 57 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01966757, a study of Batten's Disease and Neuronal Ceroid Lipofuscinosis, has completed, sponsored by Nationwide Children's Hospital.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
Neuronal Ceroid Lipofuscinosis (NCL) also known at Batten's disease is the most common neurodegenerative disorder in children. Families often report the patient has a sleep disturbance. This is a questionnaire to be completed by the family to better understand the sleep pattern and sleep difficulties experienced by individuals who have been diagnosed with NCL.
Primary Outcome
Identify the presence of sleep disturbance in children with Neuronal Ceroid Lipofuscinosis using the Children's Sleep Habits Questionnaire (CSHQ) and using the 8 subscales further identify specific areas of difficulty
Conditions Studied
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-07 |
What the finished NCT01966757 record still lists
NCT01966757 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 2 conditions, with Batten's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01966757 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01966757 about?
NCT01966757 is a clinical study titled "Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities". Neuronal Ceroid Lipofuscinosis (NCL) also known at Batten's disease is the most common neurodegenerative disorder in children. Families often report the patient has a sleep disturbance. This is a questionnaire to be completed by the family to better understand the sleep pattern and sleep difficultie...
What is the current status of trial NCT01966757?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2013-07. Estimated completion is 2016-07.
What conditions does trial NCT01966757 study?
This clinical trial studies the following conditions: Batten's Disease, Neuronal Ceroid Lipofuscinosis.
Who is sponsoring clinical trial NCT01966757?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01966757 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Batten's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia